Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

ImmunoPrecise Antibodies Reports A 19.9% Revenue Increase As It Launches The Next Phase Of LENSai Portal And SaaS Platforms

VICTORIA, BC / ACCESSWIRE / January 10, 2024 / ImmunoPrecise Antibodies (NASDAQ: IPA) ("IPA"), a leading company in AI-driven biotherapeutic research and technology, has recently provided an update to investors as it reported earnings for Q2 FY2024. The company is known for its pioneering work as a Contract Research Organization (CRO) in the biopharmaceutical industry, particularly distinguished for its adeptness in integrating Vertical AI, a concept that intertwines industry-specific knowledge with artificial intelligence (AI).

IPA's strategy of providing a full continuum of end-to-end antibody discovery and development services utilizing a combination of AI and wet lab technologies seems to be yielding positive outcomes. In the recent quarter, the company achieved revenues of CA$6.2 million and CA$11.8 million for the three- and six-month periods ending on October 31, 2023, respectively. These figures represent year-over-year increases of 18.6% and 19.9%, surpassing the revenues of CA$5.2 million and CA$9.9 million generated during the same periods in 2022. This marks the third consecutive quarter in which IPA experienced record revenue. The laboratory revenue of IPA Canada rose by 17%, while its manufacturing facility in Utrecht, The Netherlands achieved a 43% growth in revenue, solidifying its expansion strategy to meet global customer demands.

The company's AI subsidiary, BioStrand is generating revenue through its LENSai platform by providing fee-for-service while also making progress on their software deliverable to cater to IPA's client base of more than 600 companies. The unique feature of LENSai is its ability to connect the fundamental pillars of the biosphere into one comprehensive framework. These pillars consist of biological sequences, protein structure and protein functions. LENSai, powered by BioStrand's patented HYFTs™ technology, seamlessly integrates vast amounts of multi-omics data, enabling unparalleled analysis in the field of life science discovery. During the second quarter of FY24, BioStrand introduced two significant services: high-throughput in silico epitope mapping and binning. In addition, its software as a service (SaaS) model will have a broader public rollout, with comprehensive data management capabilities and analytical tools.

As of 2022, the global drug discovery market was worth $81.5 billion, and it is expected to reach $181.4 billion by 2032. The patented technology behind IPA, as well as the company's innovative approach to modern medicine, potentially positions the company to become an industry leader.

All numbers are expressed in Canadian dollars.

Featured photo by Braňo on Unsplash.

Contact:

investors@ipatherapeutics.com

SOURCE: ImmunoPrecise Antibodies Ltd.



View the original press release on accesswire.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.